Page 1 of Clinical Trials for Gastroesophageal Junction Cancer, 184 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Active, not recruiting
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Last Updated: February 1, 2012
Condition(s): Gastric Cancer; Esophageal Cancer
2
Recruiting
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Last Updated: April 18, 2012
Condition(s): Esophageal Cancer; Gastroesophageal Junction Cancer
3
Active, not recruiting
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Last Updated: February 3, 2010
Condition(s): Locally Advanced Esophageal or GE Junction Cancer
4
Recruiting
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Last Updated: May 24, 2012
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
5
Active, not recruiting
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Last Updated: February 16, 2010
Condition(s): Esophageal Cancer; Gastric Cancer
6
Recruiting
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Last Updated: February 28, 2012
Condition(s): Gastro-oesophageal Junction Cancer; Gastric Cancer
7
Recruiting
Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Last Updated: April 2, 2011
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
8
Active, not recruiting
Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer
Last Updated: May 9, 2009
Condition(s): Esophageal Cancer; Gastrointestinal Complications
9
Terminated
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Last Updated: February 8, 2010
Condition(s): Gastric Cancer; Esophageal Cancer; Tumors
10
Recruiting
Epirubicin, Oxaliplatin, and Capecitabine or Docetaxel and Oxaliplatin in Treating Patients With Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, or Stomach Cancer
Last Updated: June 30, 2010
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
11
Not yet recruiting
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
Last Updated: April 25, 2012
Condition(s): Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
12
Active, not recruiting
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Last Updated: February 14, 2012
Condition(s): Esophageal Cancer
13
Completed
T900607 in Treating Patients With Gastroesophageal Junction Cancer
Last Updated: February 12, 2011
Condition(s): Gastric Cancer
14
Recruiting
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer
Last Updated: August 29, 2009
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
15
Recruiting
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Last Updated: February 2, 2010
Condition(s): Esophageal Cancer
16
Recruiting
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Last Updated: February 22, 2011
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
17
Recruiting
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Last Updated: June 23, 2011
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
18
Recruiting
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer
Last Updated: May 24, 2012
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
19
Active, not recruiting
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Last Updated: January 24, 2012
Condition(s): Gastric Cancer
20
Active, not recruiting
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Last Updated: April 7, 2011
Condition(s): Esophageal Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Gastroesophageal+Junction+Cancer

Page 1 of Clinical Trials for Gastroesophageal Junction Cancer, 184 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About